Lava Therapeutics

Investment area
Novo Ventures
Region
Europe
Date of investment
August 2020

Developing next generation bispecific gamma-delta T cell engaging (bsTCE) antibodies to fight cancer.

Lava Therapeutics

Investment area
Novo Ventures
Region
Europe
Date of investment
August 2020

Developing next generation bispecific gamma-delta T cell engaging (bsTCE) antibodies to fight cancer.

Lava Therapeutics

Investment area
Novo Ventures
Region
Europe
Date of investment
August 2020

Developing next generation bispecific gamma-delta T cell engaging (bsTCE) antibodies to fight cancer.